Pichichero M E
Department of Microbiology and Immunology, University of Rochester Medical Center, NY 14642, USA.
Am Fam Physician. 1995 Nov 1;52(6):1739-46.
Traditional antibiotics such as amoxicillin, tetracycline and erythromycin remain the drugs of first choice for most bacterial respiratory infections. However, the usefulness of these agents varies, depending on local bacterial resistance patterns and patient factors. In the United States, amoxicillin and penicillin resistance currently occurs in 20 to 30 percent of Streptococcus pneumoniae strains, 30 to 40 percent of Haemophilus influenzae strains and 70 to 90 percent of Moraxella catarrhalis strains. For infections with these pathogens, selective use of the newer extended-spectrum oral antibiotics may be indicated. Cefuroxime axetil (a second-generation cephalosporin), cefpodoxime (a third-generation cephalosporin), amoxicillin-clavulanate (a beta-lactamase inhibitor combination agent) and clarithromycin or azithromycin (extended-spectrum macrolides) are all relatively effective against organisms that are commonly resistant to penicillin and amoxicillin.
传统抗生素如阿莫西林、四环素和红霉素仍是大多数细菌性呼吸道感染的首选药物。然而,这些药物的有效性各不相同,这取决于当地的细菌耐药模式和患者因素。在美国,目前20%至30%的肺炎链球菌菌株、30%至40%的流感嗜血杆菌菌株以及70%至90%的卡他莫拉菌菌株对阿莫西林和青霉素耐药。对于这些病原体引起的感染,可能需要选择性地使用新型广谱口服抗生素。头孢呋辛酯(第二代头孢菌素)、头孢泊肟(第三代头孢菌素)、阿莫西林-克拉维酸(一种β-内酰胺酶抑制剂复方制剂)以及克拉霉素或阿奇霉素(广谱大环内酯类)对通常对青霉素和阿莫西林耐药的微生物都相对有效。